Rivaroxaban inhibits Factor Xa, whereas VKAs inhibit the glycosylation of multiple vitamin K-dependent coagulation proteins. TF: Tissue factor; VKA: Vitamin K antagonist.

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...

Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

J&J has said it will now need upfront payment in full for its anticoagulant Xarelto (rivaroxaban) and immunology therapy Stelara (ustekinumab), with a rebate paid later, rather than the previous ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.

Other novel agents, such as rivaroxaban (an activated factor X inhibitor) and dabigatran (a direct thrombin inhibitor), are orally administered and do not require laboratory monitoring.

We excluded studies with patients with edge-to-edge MVr, those with pre-existing indication for anti-coagulation, if patients received a concomitant cardiac procedure requiring anti-coagulation and ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...